High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

NCT05895201 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI has left IU with no plan to initiate study at IU

Conditions

Bone Marrow Transplant Complications
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia, Adult
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Sitagliptin
DRUG: Bortezomib
DRUG: Cyclophosphamide

Sponsor

Indiana University